Top Line Data Anticipated News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Top line data anticipated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Top Line Data Anticipated Today - Breaking & Trending Today

Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis

Oxurion Announces the Continuation of KALAHARI Phase 2, Part B Study in Diabetic Macular Edema Following Interim Analysis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Region Flamande , Tom Graney , Westwickechristopher Brinzeytel , Usconway Communicationsbeth Kurth , Oxurion Nvtom Graneychief , Company Annual , Data Monitoring Committee , Wall Street , Top Line Data Anticipated , Euronext Brussels , Independent Data Monitoring Committee , Andy De Deene , Chief Development Officer , Chief Executive Officer , Macular Edema , Optical Coherence Tomography , Central Subfield Thickness , Graneychief Executive Officertel , Dillenchief Business Officertel , Communicationsbeth Kurth , Christopher Brinzeytel ,

Sierra Oncology Reports 2020 Year End Results

Sierra Oncology Reports 2020 Year End Results
News provided by
Share this article
Share this article
– MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 –
– Data Presented Throughout the Year Included Long-Term Overall Survival, Efficacy in Various
Patient Subsets and Dosing Durability –
– Key Appointments Made to Executive Team in Preparation for Commercial Execution –
SAN MATEO, Calif., March 11, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operational results for the fourth quarter and fiscal year ended December 31, 2020. ....

United States , William Turner , Christina Thomson , Kevin Norrett , Exchange Commission , American Society Of Hematology , Sierra Oncology Inc , European Hematology Association , Pioneer Fund , Gilead Sciences Inc , Complete Enrollment , Top Line Data Anticipated , Data Presented Throughout , Year Included Long Term Overall Survival , Dosing Durability , Key Appointments Made , Executive Team , Commercial Execution , Stephen Dilly , American Society , Upcoming Business , Chief Executive Officer , Chief Business Officer , General Counsel , Chief Regulatory , Technical Operations Officer ,

PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX₁₀₀ for the Prevention of .
PolyPid Ltd.December 16, 2020 GMT
Enrollment in SHIELD I, the First Phase 3 Clinical Trial Continues to Progress, with Top-line Data Anticipated in Second Half of 2021
PETAH TIKVA, Israel, Dec. 16, 2020 (GLOBE NEWSWIRE) PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that the first patient has been enrolled and randomized in the SHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-plex) trial, the Company’s second of two Phase 3 clinical trials for its lead product candidate, D-PLEX100, for the prevention of post-abdominal surgery incisional infection (soft tissue). ....

United States , Dikla Czaczkes Akselbrad , Anthony Senagore , Noam Emanuel , Amir Weisberg , Bob Yedid Lifesci , Exchange Commission , Drug Administration , Polypid Ltd , First Phase , Trial Continues , Top Line Data Anticipated , Second Half , Breakthrough Therapy Designation , New Drug Application , Qualified Infectious Disease Product , Fast Track , Polymer Lipid Encapsulation , Chief Scientific Officer , Private Securities Litigation Reform Act , Fast Track Designation , Bob Yedid Lifesci Advisors , ஒன்றுபட்டது மாநிலங்களில் , நோம் இமானுவேல் , அமீர் வெயிஸ்பெர்க் , பரிமாற்றம் தரகு ,